NKT2152

Clear Cell

NiKang Therapeutics, Inc.Phase 1/2Active

CCC

48/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 95/ 100

Competitive context

13 Active assets in the Clear Cell cohort.

Asset / Sponsor	Phase	Rating
Carboplatin Dana-Farber Cancer Institute	Phase 2	B
Rucaparib North Eastern German Society of Gynaecological Oncology	Phase 3	B
Dostarlimab Yonsei University	Phase 2	CCC
Lorigerlimab MacroGenics	Phase 2	CCC
Inno-206 Yonsei University	Phase 2	CCC

View all 20 →

Same molecule, other indications

NKT2152 is also rated in:

nonpapillary renal cell carcinomaDormant

B

Indicative ·

57 / 100

kidney neoplasmDormant

B

Indicative ·

57 / 100

renal cell carcinomaDormant

B

Indicative ·

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.